• English (Australia)
    • German (Austria)
    • Dutch (Belgium)
    • English (Belgium)
    • French (Belgium)
    • German (Belgium)
    • English (Canada)
    • Danish (Denmark)
    • French (France)
    • German (Germany)
    • Greek (Greece)
    • Italian (Italy)
    • Dutch (Netherlands)
    • Polish (Poland)
    • English (Singapore)
    • Spanish (Spain)
    • Swedish (Sweden)
    • French (Switzerland)
    • German (Switzerland)
    • Italian (Switzerland)
    • Chinese (Taiwan)

You are leaving this website

You are leaving this website and entering another website. Amgen is not responsible for the content or adopting such content into this website.

Go back Continue
Xalute Logo Xalute Logo
  • About the study
  • FAQ
  • Patient Resources
  • Site Resources
  • See if you qualify

Site Resource Centre

Xaluritamig is a novel T-cell engager immunotherapy being developed for advanced prostate cancer. Xaluritamig activates the immune system against prostate cancer cells by creating an immune synapse between immune T cells and STEAP1, a protein that is uniquely over-expressed in prostate cancer cells.1-3





The resources below are intended to support the XALute Study staff.

Patient recruitment materials

Recruitment PosterRecruitment Poster

Recruitment poster

Understanding Clinical Trials BookletUnderstanding Clinical Trials Booklet

Understanding clinical trials booklet

Patient engagement materials

Study Introduction TrifoldStudy Introduction Trifold

Study Introduction Trifold

Caregiver BrochureCaregiver Brochure

Caregiver brochure

Understanding Your Study BookletUnderstanding Your Study Booklet

Understanding your study booklet

Patient Safety FlyerPatient Safety Flyer

Patient safety flyer

Patient Facing Milestone NewslettersPatient Facing Milestone Newsletters

Patient-facing milestone newsletters

Appointment Reminder CardAppointment Reminder Card

Appointment reminder card

Thank You CardThank You Card

Thank you card

1 Kelly WK, Danila DC, Lin CC, et al. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from dose exploration in a first-in-human study. Cancer Discov. 2024;14(1):76-89. doi: 10.1158/2159-8290

2 Nolan-Stevaux O, Li C, et al. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov.2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290

3 Xu M, Evans L, Bizzaro CL, et al. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Cancers (Basel).2022;14(16):4034. doi: 10.3390/cancers14164034

You are leaving this website

You are leaving this website and entering another website. Amgen is not responsible for the content or adopting such content into this website.

Go back Continue
Back to Top
Amgen Logo Xalute Logo
Contact Us Terms of Use Privacy Statements Cookie Settings

© 2025 Amgen Inc. All rights reserved. | This site is intended for Canada residents only.